Higher type 2 diabetes-related mortality when HbA1c levels are too low.
The Accord randomised trial compared two HbA1c target values (less than 6% versus 7.0-7.9%) in about 10 000 patients with type 2 diabetes. The trial was discontinued prematurely in 2008 because the overall mortality rate was significantly higher in the "less than 6%" group (1.4% versus 1.1% per year)